natgillin/translations-raw huggingface dataset:
• adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
• odraslih i pedijatrijskih bolesnika s novodijagnosticiranom akutnom limfoblastičnom leukemijom s pozitivnim Philadelphia kromosomom (Ph+ ALL) uz kemoterapiju.
The most commonly reported ( 10%) drugrelated adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
Najčešće zabilježene nuspojave (10%) koje su povezane s primjenom lijeka, bile su u obje situacije blaga mučnina, povraćanje, proljev, bol u trbuhu, umor, bol u mišićima, grčevi u mišićima i osip.
In the adjuvant setting, Glivec was investigated in a multicentre, double-blind, long-term, placebocontrolled phase III study (Z9001) involving 773 patients.
Klinička ispitivanja kod adjuvantnog liječenja GIST-a U sklopu adjuvantnog liječenja, Glivec je ispitivan u multicentričnom, dvostrukoslijepom, dugotrajnom placebo kontroliranom ispitivanju faze III (Z9001) koje je uključivalo 773 bolesnika.
Thirty-six (36) months of Glivec treatment significantly prolonged RFS compared to 12 months of Glivec treatment (with overall Hazard Ratio (HR) = 0.46 [0.32, 0.65], p<0.0001) (Table 8, Figure 1).
Trideset i šest (36) mjeseci liječenja Glivecom značajno je produljilo preživljenje bez recidiva bolesti u usporedbi s 12 mjeseci liječenja Glivecom (uz ukupan omjer rizika = 0,46 [0,32, 0,65], p<0,0001) (Tablica 8, Slika 1).
1, sinusitis, cellulitis, upper respiratory tract infection, influenza, urinary tract infection, gastroenteritis, sepsis
1, sinusitis, celulitis, infekcija gornjih dišnih puteva, gripa, infekcija mokraćnog sustava, gastroenteritis, sepsa
Very dark yellow to brownish-orange, ovaloid, biconvex film-coated tablet with bevelled edges, debossed with “glivec” on one side.
Jako tamnožuta do smećkastonarančasta, ovalna, bikonveksna filmom obložena tableta ukošenih rubova te s utisnutom oznakom „glivec“ na jednoj strani.
Induction therapy (de novo Ph+ ALL)
Studija AAU02 Indukcijska terapija (de novo Ph+ ALL)
They are supplied in packs containing 20, 60, 120 or 180 tablets, but these may not all be available in your country.
Nalaze se u pakiranjima koja sadrže 20, 60, 120 ili 180 tableta, ali ona sva ne moraju biti dostupna u Vašoj zemlji.
G-CSF = granulocyte colony stimulating factor, VP-16 = etoposide, MTX = methotrexate, IV = intravenous, SC = subcutaneous, IT = intrathecal, PO = oral, IM = intramuscular, ARA-C = cytarabine, CPM = cyclophosphamide, VCR = vincristine, DEX = dexamethasone, DAUN = daunorubicin, 6-MP = 6-mercaptopurine, E.Coli L-ASP = L-asparaginase, PEG-ASP = PEG asparaginase, MESNA= 2-mercaptoethane sulfonate sodium, iii= or until MTX level is < 0.1 µM, q6h = every 6 hours, Gy= Gray
= u mišić, ARA-C = citarabin, CPM = ciklofosfamid, VCR = vinkristin, DEX = deksametazon, DAUN = daunorubicin, 6-MP = 6merkaptopurin, E.Coli L-ASP = L-asparaginaza, PEG-ASP = PEG asparaginaza, MESNA= natrijev 2merkaptoetan sulfonat, iii= ili dok vrijednost MTX-a ne bude <0,1 µm, Gy= Gray
If cytopenia is unrelated to leukaemia, reduce dose of Glivec to 400 mg. 3.
2. Ako citopenija nije povezana s leukemijom, dozu Gliveca treba smanjiti na 400 mg.
Patients were treated at doses of Glivec of 260 mg/m2/day (n=5), 340 mg/m2/day (n=9), 440 mg/m2/day (n=7) and 570 mg/m2/day (n=5).
Bolesnici su liječeni dozama Gliveca od 260 mg/m2/dan (n=5), 340 mg/m2/dan (n=9),
One phase II, open label, multicentre clinical trial (study B2225) was conducted including 12 patients with DFSP treated with Glivec 800 mg daily.
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II (studija B2225) koje je uključivalo 12 bolesnika s DFSP-om liječenih Glivecom 800 mg na dan.
Caution should be used when taking Glivec with protease inhibitors, azole antifungals, certain macrolides (see section 4.5), CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section
Potreban je oprez kada se Glivec uzima s inhibitorima proteaze, azolnim antimikoticima, određenim makrolidima (vidjeti dio 4.5), CYP3A4 supstratima s uskim terapijskim prozorom (npr. ciklosporin, pimozid, takrolimus, sirolimus, ergotamin, diergotamin, fentanil, alfentanil, terfenadin, bortezomib, docetaksel, kvinidin) ili varfarinom i drugim derivatima kumarina (vidjeti dio 4.5).
In rats, hyperplasia of the transitional epithelium in the renal papilla and in the urinary bladder was observed at doses  6 mg/kg in the 13-week study, without changes in serum or urinary parameters.
U ispitivanju kod štakora koje je trajalo 13 tjedana zapažena je hiperplazija prijelaznog epitela u bubrežnoj papili te u mokraćnom mjehuru uz doze ≥6 mg/kg, bez promjena parametara za serum ili mokraću.
The starting dose is 600 mg to be taken as one tablet of 400 mg plus 2 tablets of 100 mg once a day.
Početna doza je 600 mg, koja se uzima kao jedna tableta od 400 mg i 2 tablete od 100 mg jednom na dan.
Glivec 100 mg hard capsules EU/1/01/198/002-006
Glivec 100 mg tvrde kapsule EU/1/01/198/002-006
Resume treatment with Glivec at 600 mg. 3.
2. Ponovno uvesti liječenje Glivecom u dozi od 600 mg.
ANC < 1.0 x 10
ABN < 1,0 x 10
Partial 1 Haematological response criteria (all responses to be confirmed after  4 weeks): CHR: Study 0110 [WBC < 10 x 10 9/l, platelets < 450 x 10
3) [95% CI] Djelomični Kriteriji hematološkog odgovora (svi se odgovori moraju potvrditi nakon ≥4 tjedna): CHR: Studija 0110 [WBC <10 x 10
600 mg to be taken as 12 capsules once a day.
600 mg se uzima kao 12 kapsula jednom na dan.
Isolated cases of Glivec overdose have been reported spontaneously and in the literature.
Zabilježeni su spontani i literaturni izolirani slučajevi predoziranja Glivecom.
9/l, platelet < 450 x 10
9/l, trombociti <450 x 10
Treatment duration: In clinical trials in GIST patients, treatment with Glivec was continued until disease progression.
Trajanje liječenja: u kliničkim ispitivanjima na bolesnicima s GIST-om, liječenje Glivecom nastavljeno je sve do progresije bolesti.
9/l, no blood blasts, BM blasts < 5% and no extramedullary disease] NEL Same criteria as for CHR but ANC  1 x 10
blasti u KS <5% i nema ekstramedularne bolesti] NEL Isti kriteriji kao za CHR, ali je ABN 1 x 10
VCR 2 mg i.v., days 6, 13, 20; Daunorubicin 45 mg/m i.v., days 6-7, 13-14
VCR 2 mg i.v., dani 6, 13, 20; Daunorubicin 45 mg/m i.v., dani 6-7, 13-14
12-month treatment arm 36-month treatment arm
Krak s 36-mjesečnim liječenjem
The effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival.
Klinička ispitivanja kod kronične mijeloične leukemije Učinkovitost Gliveca temelji se na općim hematološkim i citogenetskim stopama odgovora i preživljenju bez progresije.
only) RTC < 15% blasts BM and PB, < 30% blasts+promyelocytes in BM and PB, < 20% basophils in PB, no extramedullary disease other than spleen and liver (only for 0102 and 0109).
9/l (samo 0102 i 0109) RTC <15% blasta u KS i PK, <30% blasta+promijelocita u KS i PK, <20% bazofila u PK, nema ekstramedularne bolesti osim u slezeni i jetri (samo za 0102 i 0109).
7, eructation, melaena, oesophagitis, ascites, gastric ulcer, haematemesis, cheilitis, dysphagia, pancreatitis
7, podrigivanje, melena, ezofagitis, ascites, želučani ulkus, hematemeza, heilitis, disfagija, pankreatitis
White to yellow powder in a light yellow to orange-yellow opaque capsule, marked “NVR SH”.
Bijeli do žuti prašak u svijetložutoj do narančastožutoj neprozirnoj kapsuli, s oznakom „NVR SH“.
Dose increases from 340 mg/m daily to 570 mg/m daily (not to exceed the total dose of 800 mg) may be considered in children in the absence of severe adverse drug reaction and severe non-leukaemiarelated neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response.
U djece se mogu razmotriti povećanja doze od 340 mg/m na dan do 570 mg/m na dan (ne smije se prekoračiti ukupna doza od 800 mg) u odsustvu teške nuspojave i teške neutropenije ili trombocitopenije nepovezanih s leukemijom u sljedećim situacijama: progresija bolesti (u bilo kojem trenutku); neuspjeh u postizanju zadovoljavajućeg hematološkog odgovora nakon liječenja u trajanju od najmanje 3 mjeseca; neuspjeh u postizanju citogenetskog odgovora nakon 12 mjeseci liječenja; ili gubitak ranije postignutoga hematološkog i/ili citogenetskog odgovora.
Overall, in patients receiving first-line Glivec, the average daily dose delivered was 406 ± 76 mg.
Ukupno gledajući, prosječna vrijednost dnevne doze dane bolesnicima koji su primali prvu liniju liječenja Glivecom iznosila je 406 ± 76 mg.
VCR (1.5 mg/m 2/day, IV): days 1, 29
VCR (1,5 mg/m 2/dan, i.v.): dani 1, 29
Paediatric chronic phase CML (at dose 340 mg/m
Pedijatrijska kronična faza KML-a (doza od 340 mg/m
Concomitant use of imatinib and medicinal products that induce CYP3A4 (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or Hypericum perforatum, also known as St. John's Wort) may significantly reduce exposure to Glivec, potentially increasing the risk of therapeutic failure.
Istodobna primjena imatiniba i lijekova koji induciraju CYP3A4 (npr. deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital ili Hypericum perforatum, poznat također kao gospina trava) može značajno smanjiti izloženost Glivecu, što potencijalno povećava rizik od neuspjeha terapije.
Glivec 100 mg hard capsules Packs containing 24, 48, 96, 120 and 180 capsules.
Pakiranja sadrže 24, 48, 96, 120 i 180 kapsula.
Glivec 50 mg hard capsules EU/1/01/198/001
Glivec 50 mg tvrde kapsule EU/1/01/198/001
Dose increases from 400 mg to 600 mg or 800 mg in patients with chronic phase disease, or from 600 mg to a maximum of 800 mg (given as 400 mg twice daily) in patients with accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe nonleukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response.
Povećanja doze od 400 mg do 600 mg ili 800 mg u bolesnika s kroničnom fazom bolesti, ili od 600 mg do maksimalno 800 mg (dano kao 400 mg dvaput na dan) u bolesnika s ubrzanom fazom ili blastičnom krizom može se razmotriti u odsustvu teške nuspojave i teške neutropenije ili trombocitopenije nepovezanih s leukemijom u sljedećim situacijama: progresija bolesti (u bilo kojem trenutku); neuspjeh u postizanju zadovoljavajućeg hematološkog odgovora nakon liječenja u trajanju od najmanje 3 mjeseca; neuspjeh u postizanju citogenetskog odgovora nakon 12 mjeseci liječenja; ili gubitak ranije postignutoga hematološkog i/ili citogenetskog odgovora.
8, hepatic necrosis
8, nekroza jetre
The dose is 800 mg per day (2 tablets), to be taken as one tablet in the morning and a second tablet in the evening.
Doza je 800 mg na dan (2 tablete), koja se uzima kao jedna tableta ujutro i druga tableta navečer.
The age of these patients ranged from 3 months to 4 years and imatinib was given at dose 50 mg daily or doses ranging from 92.5 to 340 mg/m daily.
Dob tih bolesnika bila je u rasponu od 3 mjeseca do 4 godine, a imatinib se primjenjivao u dozi od 50 mg na dan ili dozama u rasponu od 92,5 do 340 mg/m na dan.
DEX (6 mg/m2/day, PO): days 1-5; 29-33 6-MP (75 mg/m2/day, PO): days 11-56 (Withhold 6-MP during the 6-10 days of cranial irradiation beginning on day 1 of Cycle 5.
DEX (6 mg/m2/dan, p.o.): dani 1-5; 29-33 6-MP (75 mg/m2/dan, p.o.): dani 11-56 (Uskratiti 6-MP tijekom 6-10 dana kranijalne iradijacije dana 1, ciklusa 5. Započeti 6-MP 1-og dana nakon završetka kranijalne iradijacije.)
MTX 15 mg intrathecal, days 1, 8, 15, 22; Ara-C 40 mg intrathecal, days 1, 8, 15, 22; Methylprednisolone 40 mg intrathecal, days 1, 8, 15, 22
MTX 15 mg intratekalno, dani 1, 8, 15, 22; Ara-C 40 mg intratekalno, dani 1, 8, 15, 22; Metilprednizolon 40 mg intratekalno, dani 1, 8, 15, 22
Triple IT therapy (age-adjusted): days 1 and 22 VP-16 (100 mg/m2/day, IV): days 22-26
Trostruka i.t. terapija (prilagođena dobi): dani 1 i 22 VP-16 (100 mg/m2/dan, i.v.): dani 22-26
Glivec 400 mg film-coated tablets EU/1/01/198/009
Glivec 400 mg filmom obložene tablete EU/1/01/198/009
- The tablet coating is made of red iron oxide (E172), yellow iron oxide (E172), macrogol, talc and hypromellose.
- Ovojnica tablete sadrži crveni željezov oksid (E172), žuti željezov oksid (E172), makrogol, talk i hipromelozu.
Glivec 400 mg film-coated tablets PVDC/alu blisters
Glivec 400 mg filmom obložene tablete PVDC/Al blisteri
In the IFN arm, patients were treated with a target dose of IFN of 5 MIU/m 2/day subcutaneously in combination with subcutaneous Ara-C
U IFN kraku, bolesnici su liječeni ciljanom dozom IFN-a od 5 MIU/m2/dan supkutano u kombinaciji sa supkutanim Ara-C u dozi od 20 mg/m2/dan u trajanju od 10 dana/mjesec.
Posology for MDS/MPD The recommended dose of Glivec is 400 mg/day for adult patients with MDS/MPD.
Doziranje za MDS/MPD Za odrasle bolesnike s MDS/MPD-om preporučena doza Gliveca iznosi 400 mg/dan.
DEX 10 mg/m oral, days 1-5; Vindesine 3 mg/m i.v., day 1;
DEX 10 mg/m peroralno, dani 1-5; Vindezin 3 mg/m i.v., dan 1;
If cytopenia persists for 2 weeks, reduce further to 300 mg. 4.
3. Ako citopenija ustraje 2 tjedna, dozu ponovno smanjiti na 300 mg.
Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with Glivec (see section 4.5).
U bolesnika u kojih je obavljena tireoidektomija i koji primaju nadomjesnu terapiju levotiroksinom zabilježeni su klinički slučajevi hipotireoze tijekom liječenja Glivecom (vidjeti dio 4.5).
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St. John's Wort) may significantly reduce exposure to Glivec, potentially increasing the risk of therapeutic failure.
Tvari koje induciraju djelovanje CYP3A4 (npr. deksametazon, fenitoin, karbamazepin, rifampicin, fenobarbital, fosfenitoin, primidon ili Hypericum perforatum, poznat također kao gospina trava) mogu značajno smanjiti izloženost Glivecu, čime se potencijalno povećava rizik od neuspjeha terapije.
Caution should be taken when administering Glivec with inhibitors of the CYP3A4 family.
Kada se Glivec primjenjuje s inhibitorima porodice CYP3A4, potrebno je oprezno postupati.
Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain
Mučnina, proljev, povraćanje, dispepsija, bol u trbuhu
If cytopenia persists for 2 weeks, reduce further to 200 mg/m 4.
3. Ako citopenija ustraje 2 tjedna, dozu dodatno smanjiti na 200 mg/m
repeat step 1 and resume Glivec at reduced dose of 260 mg/m
9/l, treba ponoviti 1. korak i nastaviti primjenu Gliveca u smanjenoj dozi od 260 mg/m
Glivec 50 mg hard capsules Glivec 100 mg hard capsules
Glivec 50 mg tvrde kapsule Glivec 100 mg tvrde kapsule
100 vs. 98.1 100 vs. 93.0
NP 100 vs. 98,1 100 vs. 93,0
DEX (6 mg/m2/day, PO): days 1-5; 29-33 6-MP (75 mg/m2/day, PO): days 1-56 Methotrexate (20 mg/m2/week, PO): days 1, 8, 15, 22, 29, 36, 43, 50
DEX (6 mg/m2/dan, p.o.): dani 1-5; 29-33 6-MP (75 mg/m2/dan, p.o.): dani 1-56 Metotreksat (20 mg/m2/tjedan, p.o.): dani 1, 8, 15, 22, 29, 36, 43, 50
Glivec 100 mg film-coated tablets EU/1/01/198/007
Glivec 100 mg filmom obložene tablete EU/1/01/198/007
White to yellow powder in an orange to greyish-orange opaque capsule, marked “NVR SI”.
Bijeli do žuti prašak u narančastoj do sivkastonarančastoj neprozirnoj kapsuli, s oznakom „NVR SI“.
Iron oxide, red (E172) Shellac
željezov oksid, crveni (E172) šelak
Risk Level
Razina rizika bolesnika
9/l and platelets  75 x 10
9/l i trombociti 75 x 10
- The other ingredients are microcrystalline cellulose, crospovidone, hypromellose, magnesium stearate and anhydrous colloidal silica.
- Drugi sastojci su mikrokristalična celuloza, krospovidon, hipromeloza, magnezijev stearat i bezvodni koloidni silicijev dioksid.
CP 200 mg/m i.v., days 3, 4, 5; MTX 12 mg intrathecal, day 1 Remission induction DEX 10 mg/m oral, days 6-7, 13-16; VCR 1 mg i.v., days 7, 14; IDA 8 mg/m i.v.
CP 200 mg/m i.v., dani 3, 4, 5; MTX 12 mg intratekalno, dan 1 Indukcija remisije DEX 10 mg/m peroralno, dani 6-7, 13-16; VCR 1 mg i.v., dani 7, 14; IDA 8 mg/m i.v. (0,5 h), dani 7, 8, 14, 15;
G-CSF (5 μg/kg, SC): days 6-15 or until ANC > 1500 post nadir IT Methotrexate (age-adjusted): day 1 ONLY Triple IT therapy (age-adjusted): day 8, 15
G-CSF (5 μg/kg, s.c.): dani 6-15 ili do porasta ANC >1500 nakon najniže izmjerene vrijednosti i.t. metotreksat (prilagođeno dobi): SAMO dan 1
Glivec 100 mg film-coated tablets PVC/alu blisters
Glivec 100 mg filmom obložene tablete PVC/Al blisteri
Muscle spasm and cramps, musculoskeletal pain including myalgia arthralgia, bone pain
Spazam mišića i grčevi, mišićno-koštana bol uključujući mialgiju
The age of these patients ranged from newborn to 14 years and imatinib was given at dose 50 mg daily or doses ranging from 400 to 520 mg/m daily.
Dob tih bolesnika bila je u rasponu od novorođenčadi do 14 godina, a imatinib se primjenjivao u dozi od 50 mg na dan ili u dozama u rasponu od 400 do 520 mg/m na dan.
The printing ink is composed of red iron oxide (E172) and shellac.
Tinta za označivanje se sastoji od crvenog željezovog oksida (E172) i šelaka.
VCR 2 mg total dose i.v., days 1, 8, 15, 22; CP 750 mg/m i.v., days 1, 8; Prednisone 60 mg/m oral, days 1-7, 15-21;
VCR 2 mg ukupna doza i.v., dani 1, 8, 15, 22; CP 750 mg/m i.v., dani 1, 8; Prednizon 60 mg/m peroralno, dani 1-7, 15-21;
Posology for DFSP The recommended dose of Glivec is 800 mg/day for adult patients with DFSP.
Doziranje za DFSP Za odrasle bolesnike s DFSP-om preporučena doza Gliveca iznosi 800 mg/dan.
VCR (1.5 mg/m 2/day, IV): days 1, 8 and 15 DAUN (45 mg/m 2/day bolus, IV): days 1 and 2
VCR (1,5 mg/m 2/dan, i.v.): dani 1, 8, i 15 DAUN (45 mg/m 2/dan bolus, i.v.): dani 1 i 2
100 vs. 100 97.8 vs. 100
NP 100 vs. 100 97,8 vs. 100
VP-16 (100 mg/m2/day, IV): days 1-5 Ifosfamide (1.8 g/m2/day, IV): days 1-5 MESNA (360 mg/m2/dose q3h, x 8 doses/day, IV): days 1-5
VP-16 (100 mg/m2/dan, i.v.): dani 1-5 Ifosfamid (1,8 g/m2/dan, i.v.): dani 1-5 MESNA (360 mg/m2/doza svaka 3 sata x 8 doza/dan, i.v.): dani 1-5
• Severely decreased urine output, feeling thirsty (signs of kidney problems).
• jako smanjeno mokrenje, žeđ (znakovi bubrežnih problema).
Days 2, 3, 16, and 17
6 doza) iii: dani 2, 3, 16 i 17
100 vs. 98.7 100 vs. 95.5
NP 100 vs. 98,7 100 vs. 95,5
VCR 1.3 g/m2 i.v., day 1; Prednisolone 60 mg/m oral, days 1-5
VCR 1,3 g/m2 i.v., dan 1; Prednizolon 60 mg/m peroralno, dani 1-5
In the event of recurrence of ANC < 1.0 x 10
3. U slučaju da je ABN ponovno <1,0 x 10
The printing ink is composed of red iron oxide (E172), shellac, soya lecithin.
Tinta za označivanje se sastoji od crvenog željezovog oksida (E172), šelaka, sojinog lecitina.
If you are being treated for CML: Depending on your condition the usual starting dose is either 400 mg or 600 mg: 400 mg to be taken as one tablet once a day, 600 mg to be taken as one tablet of 400 mg plus 2 tablets of 100 mg once a day.
Ako se liječite zbog KML-a: Ovisno o Vašem stanju, uobičajena početna doza je ili 400 mg ili 600 mg: 400 mg se uzima kao jedna tableta jednom na dan, 600 mg se uzima kao jedna tableta od 400 mg i 2 tablete od 100 mg jednom na dan.
CPM (300 mg/m2, IV): days 29-33
CPM (300 mg/m2/dan, i.v.): dani 22-26
- The other ingredients are microcrystalline cellulose, crospovidone, magnesium stearate and anhydrous colloidal silica.
- Drugi sastojci su mikrokristalična celuloza, krospovidon, magnezijev stearat i bezvodni koloidni silicijev dioksid.
Glivec 400 mg tablets imatinib
Glivec 400 mg tablete imatinib
Iron oxide, yellow (E172) Titanium dioxide (E171)
želatina željezov oksid, žuti (E172) titanijev dioksid (E171)
In the event of recurrence of ANC < 1.0 x10
3. U slučaju da je ABN ponovno <1,0 x10
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets
Glivec 100 mg filmom obložene tablete Glivec 400 mg filmom obložene tablete
Cellulose microcrystalline Crospovidone Hypromellose Magnesium stearate Silica, colloidal anhydrous
celuloza, mikrokristalična krospovidon magnezijev stearat silicijev dioksid, koloidni, bezvodni
repeat step 1 and resume Glivec at reduced dose of 400 mg.
9/l, treba ponoviti 1. korak i nastaviti primjenu Gliveca u smanjenoj dozi od 400 mg.
9/l and platelets  20 x 10
9/l i trombociti 20 x 10
(1 h) day 1; Ara-C 60 mg/m i.v., days 22-25, 29-32
CP 500 mg/m i.v.(1 h) dan 1; Ara-C 60 mg/m i.v., dani 22-25, 29-32
repeat step 1 and resume Glivec at reduced dose of 300 mg.
9/l, treba ponoviti 1. korak i nastaviti primjenu Gliveca u smanjenoj dozi od 300 mg.
If you are being treated for CML: Depending on your condition the usual starting dose is either 400 mg or 600 mg: 400 mg to be taken as 8 capsules once a day.
Ako se liječite zbog KML-a: Ovisno o Vašem stanju, uobičajena početna doza je ili 400 mg ili 600 mg: 400 mg se uzima kao 8 kapsula jednom na dan.
Glivec 100 mg tablets imatinib
Glivec 100 mg tablete imatinib
- if you experience bruising, bleeding, fever, fatigue and confusion when taking Glivec, contact your doctor.
Prije početka liječenja liječnik će pažljvo pregledati bolesnike radi utvrđivanja eventualnih znakova te infekcije. - ako dobijete modrice, krvarenje, vrućicu, umor i smetenost prilikom uzimanja Gliveca, kontaktirajte liječnika.
(24 h), day 4; DEX 40 mg/day on days 1-4 and 11-14, alternated with MTX 1 g/m i.v.
Vinkristin 2 mg i.v., dani 4, 11; Doksorubicin 50 mg/m i.v. (24 h), dan 4; DEX 40 mg/dan na dane 1-4 i 11-14, izmjenjivano s MTX 1 g/m i.v.
What Glivec looks like and contents of the pack Glivec 50 mg capsules are light yellow to orange-yellow and marked “NVR SH”.
Glivec 50 mg kapsule su svijetložute do narančastožute, s oznakom „NVR SH“.
Iron oxide, red (E172) Iron oxide, yellow (E172) Titanium dioxide (E171)
želatina željezov oksid, crveni (E172) željezov oksid, žuti (E172) titanijev dioksid (E171)
CP 200 mg/m i.v., days 3-5; MTX 15 mg intrathecal, day 1 Induction therapy I DEX 10 mg/m oral, days 1-5;
CP 200 mg/m i.v., dani 3-5; MTX 15 mg intratekalno, dan 1 Indukcijska terapija
DEX 10 mg/m oral, days 1-5;
DEX 10 mg/m peroralno, dani 1-5;
If you are being treated for Ph-positive ALL: The starting dose is 600 mg to be taken as 12 capsules once a day.
Ako se liječite zbog Ph-pozitivnog ALL-a: Početna doza je 600 mg, koja se uzima kao 12 kapsula jednom na dan.
Glivec 100 mg hard capsules
Glivec 100 mg tvrde kapsule
VM26 60 mg/m i.v.
VM26 60 mg/m i.v. (1 h), dani 1-5
Ara-C 75 mg/m i.v.
Ara-C 75 mg/m i.v. (1 h), dani 1-5;
MTX (5 g/m over 24 hours, IV): day 1 Leucovorin (75 mg/m at hour 36, IV; 15 mg/m
MTX (5 g/m kroz 24 sata, i.v.): dan 1 Leucovorin (75 mg/m u 36. satu, i.v.; 15 mg/m i.v. ili p.o. svakih 6 sati x
• Feeling light-headed, dizzy or fainting (signs of low blood pressure).
• osjećaj da Vam se vrti u glavi, omaglica ili nesvjestica (znakovi sniženog krvnog tlaka).
The capsule shell is composed of gelatin, yellow iron oxide (E172) and titanium dioxide (E171).
Ovojnica kapsule se sastoji od želatine, žutog željezovog oksida (E172) i titanijevog dioksida (E171).
What Glivec looks like and contents of the pack Glivec 100 mg capsules are orange to greyish-orange and marked “NVR SI”.
Glivec 100 mg kapsule su narančaste do sivkastonarančaste, s oznakom „NVR SI“.
Posology for HES/CEL The recommended dose of Glivec is 100 mg/day for adult patients with HES/CEL.
Za odrasle bolesnike s HES/KEL-om preporučena doza Gliveca iznosi 100 mg/dan.
9/l, platelets  100 x 10
9/l, trombociti ≥100 x 10